MI
GRCE

Motiv8 Investments’s Grace Therapeutics GRCE Stock Holding History

Motiv8 Investments’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$0 Buy
+20
New +$64 ﹤0.01% 998

Other funds holding GRCE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Motiv8 Investments's GRCE Position: Q4 2025 in Review

Motiv8 Investments opened a new position in Grace Therapeutics (GRCE) in Q4 2025: 20 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #998 among its holdings.

23 funds tracked by Wall St. Rank hold GRCE as of Q4 2025.

  • Motiv8 Investments held 20 shares of Grace Therapeutics worth $0 as of Q4 2025.
  • Grace Therapeutics was a new Motiv8 Investments position in Q4 2025.
  • Grace Therapeutics made up ﹤0.01% of Motiv8 Investments's portfolio in Q4 2025, its #998 holding.
  • 23 funds tracked by Wall St. Rank held Grace Therapeutics as of Q4 2025.

Based on Motiv8 Investments's 13F filing for Q4 2025, filed 13 Feb 2026.